Phase II Trial Evaluates Amivantamab Plus Lazertinib in EGFR-Mutant Lung Cancers With New or Progressing Brain Metastases or Leptomeningeal Disease

… the formal response criteria. However, when we examined CSF circulating tumor cells (CTCs), 67% of patients demonstrated a reduction in tumor burden. This discordance suggests that conventional …